Repurposed drugs as adjunctive treatments for mania and bipolar depression: A meta-review and critical appraisal of meta-analyses of randomized placebo-controlled trials.

@article{Bartoli2021RepurposedDA,
  title={Repurposed drugs as adjunctive treatments for mania and bipolar depression: A meta-review and critical appraisal of meta-analyses of randomized placebo-controlled trials.},
  author={Francesco Bartoli and Daniele Cavaleri and Bianca Bachi and Federico Moretti and Ilaria Riboldi and Cristina Crocamo and Giuseppe Carr{\`a}},
  journal={Journal of psychiatric research},
  year={2021},
  volume={143},
  pages={
          230-238
        }
}
2 Citations
Markers of Fungal Translocation Are Elevated During Post-Acute Sequelae of SARS-CoV-2 Infection and Induce NF-κB Triggered Inflammation
TLDR
It is found that plasma from individuals experiencing PASC induced higher NF-κB signaling compared to plasma from SARS-CoV-2 negative controls, which suggests a potential targetable mechanism linking fungal translocation and inflammation during PASC.

References

SHOWING 1-10 OF 54 REFERENCES
Allopurinol as add-on treatment for mania symptoms in bipolar disorder: Systematic review and meta-analysis of randomised controlled trials
TLDR
The finding of a small to moderate effect size and overall low evidence for add-on allopurinol in reducing mania symptoms indicate that its use in routine practice needs further elucidation.
Comparative Efficacy and Tolerability of Adjunctive Pharmacotherapies for Acute Bipolar Depression: A Systematic Review and Network Meta-analysis
TLDR
Fluoxetine appeared to have the most consistent evidence base for both efficacy and tolerability, and there remains a need for additional research exploring novel treatment strategies for bipolar depression, particularly head-to-head studies.
Tamoxifen for bipolar disorder: Systematic review and meta-analysis
TLDR
Tamoxifen appears to be a promising potential treatment for episodes of mania, and future studies could investigate its effects as an adjunct to dopamine antagonists for improved anti-manic efficacy, and establish its longer term effects on mood, particularly depression and relapse.
Supraphysiologic doses of levothyroxine as adjunctive therapy in bipolar depression: a randomized, double-blind, placebo-controlled study.
TLDR
This trial demonstrated that patients treated with levothyroxine did numerically better than those treated with placebo; however, the study failed to detect a statistically significant difference between the 2 groups in the primary outcome measure due to a high placebo response rate.
Effect of Rivastigmine (Acetyl Cholinesterase Inhibitor) versus Placebo on Manic Episodes in Patients with Bipolar Disorders: Results from a Double Blind, Randomized, Placebo-Controlled Clinical Trial
TLDR
Adjuvant rivastigmine, a cholinesterase inhibitor, improved symptoms of mania among a larger sample of inpatients with BPD and in the acute manic state, however, the improvements were modest.
Treatment of bipolar depression with minocycline and/or aspirin: an adaptive, 2×2 double-blind, randomized, placebo-controlled, phase IIA clinical trial
TLDR
Aspirin and minocycline may be efficacious adjunctive treatments for bipolar depression given their potential import, studies to confirm and extend these findings are warranted.
A review of the use of stimulants and stimulant alternatives in treating bipolar depression and major depressive disorder.
TLDR
The promising results of 1 recent lisdexamfetamine RCT, when considered in the context of the deleterious effect of subsyndromal depression, suggest consideration of dopaminergic medications in treatment-refractory unipolar or bipolar depression when modafinil is cost prohibitive or otherwise contraindicated.
...
...